Display options
Cite
Nihei J, Cardillo F, Dos Santos WL, et al. Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi. Eur J Microbiol Immunol (Bp). 2014;4(2):128-37doi: 10.1556/EuJMI.4.2014.2.6.
Nihei, J., Cardillo, F., Dos Santos, W. L., Pontes-de-Carvalho, L., & Mengel, J. (2014). Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi. European journal of microbiology & immunology, 4(2), 128-37. https://doi.org/10.1556/EuJMI.4.2014.2.6
Nihei, J, et al. "Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi." European journal of microbiology & immunology vol. 4,2 (2014): 128-37. doi: https://doi.org/10.1556/EuJMI.4.2014.2.6
Nihei J, Cardillo F, Dos Santos WL, Pontes-de-Carvalho L, Mengel J. Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi. Eur J Microbiol Immunol (Bp). 2014 Jun;4(2):128-37. doi: 10.1556/EuJMI.4.2014.2.6. Epub 2014 May 21. PMID: 24883199; PMCID: PMC4029292.
Copy Download .nbib Format: NLM
Share it on

Eur J Microbiol Immunol (Bp). 2014 Jun;4(2):128-37. doi: 10.1556/EuJMI.4.2014.2.6. Epub 2014 May 21.

Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi.

European journal of microbiology & immunology

J Nihei, F Cardillo, W L C Dos Santos, L Pontes-de-Carvalho, J Mengel

PMID: 24883199 PMCID: PMC4029292 DOI: 10.1556/EuJMI.4.2014.2.6

Abstract

The role of CD25+ regulatory T cells during the course of Trypanosoma cruzi infection has been previously analyzed, and the bulk of results have shown a limited role for this T cell subpopulation. In this study, we have used an IgM, nondepleting monoclonal antibody (mAb) aiming at blocking interleukin (IL)-2 activity on CD25+ T cells. The administration of this antibody 10 days before infection increased the resistance of outbred Swiss mice to the Colombian strain of T. cruzi. Anti-CD25-treated mice had lower parasitemia and augmented numbers of effector memory T cells. In addition, these animals showed higher numbers of splenic T cells secreting IFN-γ and TNF-α, both cytokines described to be involved in the resistance to T. cruzi infection. The same treatment also increased the numbers of splenic T cells that produced homeostatic and regulatory cytokines, such as IL-2 and IL-10, and CD4+CD25+ T cells. The administration of nondepleting anti-CD25 mAb at the beginning of the chronic phase, when parasites were cleared from the blood, halted the inflammatory process in the heart, without any signs of infection reactivation. These results indicate that nondepleting anti-CD25 monoclonal antibodies may be useful to treat chronic Chagas' disease.

Keywords: Trypanosoma cruzi; anti-CD25; interleukin 10; mice; monoclonal antibody; regulatory T cells

References

  1. Autoimmunity. 2006 Feb;39(1):41-54 - PubMed
  2. Annu Rev Immunol. 2008;26:453-79 - PubMed
  3. PLoS One. 2010 Jul 30;5(7):e11784 - PubMed
  4. Microbes Infect. 2008 May;10(6):680-8 - PubMed
  5. Cardiovasc Res. 2011 Jul 1;91(1):116-23 - PubMed
  6. Microbes Infect. 2008 Jun;10(7):825-33 - PubMed
  7. Nat Immunol. 2005 Nov;6(11):1142-51 - PubMed
  8. Immunity. 2013 Jan 24;38(1):13-25 - PubMed
  9. J Infect Dis. 1999 Aug;180(2):480-6 - PubMed
  10. J Immunol. 2012 Oct 1;189(7):3669-80 - PubMed
  11. FEMS Immunol Med Microbiol. 2004 May 1;41(1):69-77 - PubMed
  12. Eur J Immunol. 2007 Jul;37(7):1817-26 - PubMed
  13. J Exp Med. 2008 Nov 24;205(12):2887-98 - PubMed
  14. J Immunol. 2003 Mar 1;170(5):2264-8 - PubMed
  15. Immunobiology. 2012 Aug;217(8):768-77 - PubMed
  16. J Immunol. 2006 Mar 15;176(6):3301-5 - PubMed
  17. Immunology. 2008 Oct;125(2):184-96 - PubMed
  18. Exp Parasitol. 1996 Nov;84(2):231-44 - PubMed
  19. Cell Microbiol. 2012 May;14(5):634-43 - PubMed
  20. Cytokine. 2013 Jan;61(1):304-14 - PubMed
  21. Infect Immun. 1996 Jan;64(1):128-34 - PubMed
  22. Parasitol Today. 1999 Mar;15(3):94-9 - PubMed
  23. Infect Immun. 2007 Feb;75(2):861-9 - PubMed
  24. Trends Immunol. 2011 Jun;32(6):278-86 - PubMed
  25. J Immunol. 2012 Jan 15;188(2):649-60 - PubMed
  26. Microbes Infect. 2007 Jul;9(9):1104-13 - PubMed
  27. Scand J Immunol. 2002 Jan;55(1):96-104 - PubMed
  28. Eur J Immunol. 1993 Oct;23(10):2597-605 - PubMed
  29. Immunity. 2009 May;30(5):636-45 - PubMed
  30. Parasite Immunol. 2001 Feb;23(2):93-101 - PubMed
  31. PLoS One. 2011;6(12):e28513 - PubMed
  32. J Neuroimmunol. 2007 Aug;188(1-2):48-55 - PubMed
  33. Annu Rev Immunol. 2009;27:29-60 - PubMed
  34. J Immunol. 2002 Nov 1;169(9):4850-60 - PubMed
  35. J Immunol. 1997 Apr 1;158(7):3311-6 - PubMed
  36. Clin Immunol. 2012 Jan;142(1):9-14 - PubMed
  37. Nat Rev Immunol. 2012 Feb 17;12(3):180-90 - PubMed
  38. Nat Immunol. 2010 Sep;11(9):862-71 - PubMed
  39. J Immunol. 2006 Aug 15;177(4):2036; author reply 2037-8 - PubMed
  40. Immunity. 2009 Jun 19;30(6):899-911 - PubMed

Publication Types